MNMartha A. Nance

Martha A. Nance

*This is an algorithmically generated author record based on publicly available information.

Martha A. Nance has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PD GENEration: An International Parkinson’s Disease Genetic Research Study

    by Kamalini Ghosh Galvelis, Allison A. Dilliott, Megan Dini, Rebeca De León, Max Thom, Ignacio Azcarate, Nicola Bothwick, Lark Caboy, Anny Coral-Zambrano, Kirby Doshier, et al.

    Background: PD GENEration ( NCT04057794 , NCT04994015 ), sponsored by the Parkinson’s Foundation in partnership with Aligning Science Across Parkinson’s (ASAP) through the Global Parkinson’s Genetics Program (GP2), is an international, observational, clinical research study that offers genetic testing and counseling to people living with Parkinson’s disease (PwP) at no cost. PD GENEration has aimed to empower PwP and their clinicians with knowledge of their genetic status, to accelerate recruitment into precision medicine trials, and to advance research through data sharing. Since its launch in 2019, the study has expanded to enroll over 32,000 PwP (as of March 31, 2026), from 10 countries across North, Central, and South America, the Caribbean, and Israel. Methods: Over the course of 6 years, PD GENEration has evolved to accommodate the growing scientific and research needs of the Parkinson’s community while also increasing the ability to return genetic test results to PwP at a greater scale. Participants with a diagnosis of Parkinson’s disease (PD) may enroll in-person or virtually where informed consent and blood sample collection can occur. Samples are analyzed at a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA)-certified laboratory using whole genome sequencing, with variants curated for a primary panel of seven PD-associated genes. Results are disclosed during a genetic counseling visit, where further testing is offered for two optional additional gene panels. Those who consent undergo analysis of additional genes, and results are returned during a genetic counseling visit for those that test positive for a variant. In addition to returning genetic results to PwP, a central pillar of the study design has been the open sharing of genomic data to advance discovery in PD research in partnership with ASAP and GP2. Discussion: PD GENEration applies a flexible framework, allowing for country specific considerations and the integration of multiple site models, evolving based on participant needs and the prioritization of equity and accessibility. We summarize PD GENEration’s implementation and scaling, highlight key accomplishments and lessons learned, and provide guidance for those interested in implementing large-scale clinical genetic testing studies across other diseases and therapeutic domains.


  • Open Access

    Change in movement disorder specialist attitudes to genetic testing after implementation of PD GENEration

    by Jesse Wang, Vanessa Ibrahim, Roy N. Alcalay, Julian P Agin-Liebes, Martha Nance, James C. Beck, Margaret E. Caulfield, Anna Naito, Kamalini Ghosh Galvelis, Anne-Marie Wills

    Purpose: Despite advances in recent years, genetic testing for Parkinson’s disease (PD) is still underutilized in clinical practice. A 2019 questionnaire of movement disorder specialists found low rates of genetic testing in PD and barriers such as cost and insurance coverage. Since that time, PD GENEration as well as several international programs have broadly increased access to genetic testing and counseling for people with PD. A new survey sent out in 2024 examined how genetic testing for PD has changed over the past 5 years. Methods: Between October 2024-January 2025, 621 movement disorders specialists from the Parkinson’s Study Group (PSG) were invited by email to complete a questionnaire assessing knowledge, attitudes, and barriers to genetic testing in PD based on the 2019 survey. Results: 119 total PSG clinicians from the United States and Canada responded to the questionnaire. When compared to results from 2019, 2024 survey respondents reported increased comfort and willingness to order genetic testing, including reduced fears of negative repercussions. PD GENEration-affiliated sites reported significantly higher genetic testing volume and patients with known genetic variants. Conclusions: 2024 survey respondents report greater comfort with genetic testing in PD compared to 2019, concurrent with the launch of PD GENEration.

  • Delivering Genetic Test Results for Parkinson Disease

    by Mandy Miller, Lola Cook, Jennifer Verbrugge, Priscila D. Hodges, Katharine J. Head, Martha A. Nance

    The PD GENEration (PD GENE) study (NCT04057794) is an interventional clinical trial offering genetic testing with result disclosure and genetic counseling to individuals with Parkinson disease (PD). In general, experiences of those providing PD genetic testing and counseling in a research or clinical setting have not been extensively evaluated. In this study, providers' experiences when providing research result disclosure and genetic counseling to people with PD were explored with the goal of improving PD genetics services. Qualitative semistructured interviews of all neurologists and genetic counselors who performed genetic test result disclosure and genetic counseling to at least 5 participants in the pilot portion of the PD GENE study were conducted. An inductive thematic analysis of the transcribed interviews identified core themes and subthemes for "lessons learned" and "challenges encountered." Interviews were conducted with 14 providers (7 neurologists and 7 genetic counselors) who described multiple lessons learned while disclosing genetic test results, including the ability to adapt to participant background and needs and the value of a well-structured and supportive study that also provides training and educational materials for the provider. Of importance, responses suggested that the PD GENE study answered a real need, highlighting a strong interest in the community. Providers also voiced several shared challenges including the complexities of PD and PD genetics, unexpected confusion on provider roles within a research study, and complicated family histories/dynamics. Providers in the pilot portion of the PD GENE study encountered enthusiasm and strong engagement from many of the participants, and they, too, voiced significant satisfaction about their roles and the mission of the study. They learned valuable lessons, and their comfort providing genetic test result disclosure and genetic counseling grew as the study progressed. Although there were challenges, they were deemed manageable. The results from this qualitative study can inform both the expanded PD GENE study and other providers offering genetic testing and counseling to their patients in a neurology setting. It will also allow for targeted PD provider education.


  • Open Access

    Providing genetic testing and genetic counseling for Parkinson’s disease to the community

    by Lola Cook, Jennifer Verbrugge, Tae-Hwi Schwantes-An, Jeanine Schulze, James C. Beck, Anna Naito, Anne Hall, Amanda K. Chan, Cynthia J. Casaceli, Karen Marder, et al.


  • Coordination of Care Among Physical Therapists and Neurologists in Huntington Disease

    by Nora E. Fritz, Deb Kegelmeyer, Ashwini K. Rao, Lori Quinn, Martha A. Nance, Anne Kloos

    This paper presents a framework for physical therapy through the course of Huntington’s disease (HD) which includes coordinated care plans with neurologists. HD is an inherited neurodegenerative disorder that leads to impaired strength and coordination and ultimately progressive loss of function. Interdisciplinary HD care teams provide patient-centered, comprehensive evaluations and make recommendations for pharmacological, healthcare and lifestyle interventions based on best available evidence. Physical therapists work to improve movement and mobility using specific therapeutic interventions and individualized exercise programs. The proposed framework recommends that neurologists refer persons with HD to physical therapy at all disease stages, ideally beginning in premanifest and early stages, and that they regularly communicate with physical therapists to ensure implementation of a coordinated care plan. Resources are provided for neurologists to facilitate appropriate referral for individuals with HD to physical therapy based on clinical practice guidelines, including a referral decision guide.


  • Attention training improves attention and gait in Parkinson disease: A pilot study

    by Catherine L. Wielinski, Richard VandenDolder, Lora McManus, Martha A. Nance, Rosemary Wichmann, Sotirios A. Parashos